Journal
AMERICAN JOURNAL OF GASTROENTEROLOGY
Volume 106, Issue 1, Pages 38-45Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1038/ajg.2010.370
Keywords
-
Categories
Funding
- Duke Clinical Research Institute
- Richard B. Boebel Family Fund
- Gastroenterology Society of Australia
- National Health and Medical Research Council of Australia
- Royal Australasian College of Physicians
- Schering-Plough Research Institute, Kenilworth, New Jersey
Ask authors/readers for more resources
Genome-wide association studies (GWAS) have recently identified host genetic variation to be critical for predicting treatment response and spontaneous clearance in patients infected with hepatitis C virus (HCV). These important new studies are reviewed and their future clinical implications discussed. Single-nucleotide polymorphisms in the region of the IL28B gene on chromosome 19, coding for the interferon (IFN)-lambda-3 or IL28B gene, are strongly associated with treatment response to pegylated IFN and ribavirin in patients infected with genotype 1 HCV. The good response variant is associated with a twofold increase in the rate of cure. Allele frequencies differ between ethnic groups, largely explaining the observed differences in response rates between Caucasians, African Americans and Asians. IL28B polymorphism is also strongly associated with spontaneous clearance of HCV. The biological mechanisms responsible for these genetic associations remain unknown and are the focus of ongoing research. Knowledge of a patient's IL28B genotype is likely to aid in clinical decision making with standard of care regimens. Future studies will investigate the possibility of individualizing treatment duration and novel regimens according to IL28B type.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available